Observing the natural history of chordoma in children and adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather comprehensive clinical, epidemiologic, and biological data on chordoma, a rare bone cancer affecting the skull base or spine. Participants aged 2 and older with documented chordoma will undergo a series of evaluations, including physical and neurologic exams, imaging scans, and periodic assessments of their well-being. The goal is to better understand the disease's progression and response to treatments, ultimately informing future therapeutic strategies.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written consent document.
* Subjects with radiographically or histologically documented chordoma
* Age \>= 2 years old
* Subjects must be enrolled into NCI protocol 19-C-0016: "Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors".

EXCLUSION CRITERIA:

-None

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Mary F Wedekind Malone, D.O. — National Cancer Institute (NCI)
• Study coordinator: Barbara J Thomas, R.N.
• Email: barbara.thomas2@nih.gov
• Phone: (240) 858-3633

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination treatment of pembrolizumab and high-dose pemetrexed for chordoma

  This study is testing a new combination of two drugs, pembrolizumab and high-dose pemetrexed, to see if it can help people with progressive chordoma, a rare cancer.

  Recruiting Phase 2 Saint John's Cancer Institute · Santa Monica, California · NCT06794645

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Comparing single vs double beam proton therapy for certain tumors

  This study is testing whether using one beam of proton therapy is just as effective and safer than using two beams for patients with certain types of tumors.

  Recruiting Centre Antoine Lacassagne · Nice · NCT06029218

• Proton therapy for chordomas and chondrosarcomas at the skull base

  This study is testing a new type of proton therapy to see if it can effectively treat chordomas and chondrosarcomas at the base of the skull while keeping side effects low and improving patients' quality of life.

  Recruiting Quironsalud · Madrid, Madrid · NCT05861245

• Comparing carbon ion therapy, surgery, and proton therapy for pelvic bone sarcomas

  This study is testing whether carbon ion therapy works better than surgery or proton therapy for treating pelvic bone sarcomas and how these treatments affect patients' quality of life.

  Recruiting at 3 sites Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT05033288

• Using imaging to improve proton therapy for chordomas and chondrosarcomas

  This study is testing if using advanced imaging techniques can help improve proton therapy for patients with aggressive bone tumors called chordomas and chondrosarcomas by better targeting the tumors and protecting healthy tissue.

  Recruiting at 2 sites Leiden University Medical Center · Delft, South Holland and 1 other locations · NCT04832620

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.